MedKoo Cat#: 532903 | Name: VU0360172

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VU0360172 is a positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM). VU0360172 is selective for mGlu5 and it displays no significant activity at mGlu1, mGlu2 or mGlu4 receptors.

Chemical Structure

VU0360172
VU0360172
CAS#1310012-12-4

Theoretical Analysis

MedKoo Cat#: 532903

Name: VU0360172

CAS#: 1310012-12-4

Chemical Formula: C18H15FN2O

Exact Mass: 294.1168

Molecular Weight: 294.33

Elemental Analysis: C, 73.45; H, 5.14; F, 6.45; N, 9.52; O, 5.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1310012-12-4 (free) 1309976-62-2 (HCl)
Synonym
VU0360172, VU-0360172, VU 0360172
IUPAC/Chemical Name
N-cyclobutyl-6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxamide
InChi Key
NEMHWVUKNWAKTM-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H15FN2O/c19-15-4-1-3-13(11-15)7-9-16-10-8-14(12-20-16)18(22)21-17-5-2-6-17/h1,3-4,8,10-12,17H,2,5-6H2,(H,21,22)
SMILES Code
O=C(C1=CC=C(C#CC2=CC=CC(F)=C2)N=C1)NC3CCC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 294.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Notartomaso S, Mascio G, Scarselli P, Martinello K, Fucile S, Gradini R, Bruno V, Battaglia G, Nicoletti F. Expression of the K(+)/Cl(-) cotransporter, KCC2, in cerebellar Purkinje cells is regulated by group-I metabotropic glutamate receptors. Neuropharmacology. 2017 Mar 15;115:51-59. doi: 10.1016/j.neuropharm.2016.07.032. Epub 2016 Aug 3. PubMed PMID: 27498071. 2: Sengmany K, Singh J, Stewart GD, Conn PJ, Christopoulos A, Gregory KJ. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery. Neuropharmacology. 2017 Mar 15;115:60-72. doi: 10.1016/j.neuropharm.2016.07.001. Epub 2016 Jul 5. PubMed PMID: 27392634; PubMed Central PMCID: PMC5217481. 3: D'Amore V, Raaijmakers RH, Santolini I, van Rijn CM, Ngomba RT, Nicoletti F, van Luijtelaar G. The anti-absence effect of mGlu5 receptor amplification with VU0360172 is maintained during and after antiepileptogenesis. Pharmacol Biochem Behav. 2016 Jul-Aug;146-147:50-9. doi: 10.1016/j.pbb.2016.05.004. Epub 2016 May 10. PubMed PMID: 27178815. 4: Kiritoshi T, Ji G, Neugebauer V. Rescue of Impaired mGluR5-Driven Endocannabinoid Signaling Restores Prefrontal Cortical Output to Inhibit Pain in Arthritic Rats. J Neurosci. 2016 Jan 20;36(3):837-50. doi: 10.1523/JNEUROSCI.4047-15.2016. PubMed PMID: 26791214; PubMed Central PMCID: PMC4719019. 5: D'Amore V, von Randow C, Nicoletti F, Ngomba RT, van Luijtelaar G. Anti-absence activity of mGlu1 and mGlu5 receptor enhancers and their interaction with a GABA reuptake inhibitor: Effect of local infusions in the somatosensory cortex and thalamus. Epilepsia. 2015 Jul;56(7):1141-51. doi: 10.1111/epi.13024. Epub 2015 Jun 3. PubMed PMID: 26040777. 6: Zhang ZY, Sun BL, Liu JK, Yang MF, Li DW, Fang J, Zhang S, Yuan QL, Huang SL. Activation of mGluR5 Attenuates Microglial Activation and Neuronal Apoptosis in Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats. Neurochem Res. 2015 Jun;40(6):1121-32. doi: 10.1007/s11064-015-1572-7. Epub 2015 Apr 7. PubMed PMID: 25846008. 7: Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Neuropsychopharmacology. 2015 Feb;40(3):755-65. doi: 10.1038/npp.2014.245. Epub 2014 Sep 22. PubMed PMID: 25241804; PubMed Central PMCID: PMC4289965. 8: Loane DJ, Stoica BA, Tchantchou F, Kumar A, Barrett JP, Akintola T, Xue F, Conn PJ, Faden AI. Novel mGluR5 positive allosteric modulator improves functional recovery, attenuates neurodegeneration, and alters microglial polarization after experimental traumatic brain injury. Neurotherapeutics. 2014 Oct;11(4):857-69. doi: 10.1007/s13311-014-0298-6. PubMed PMID: 25096154; PubMed Central PMCID: PMC4391388. 9: D'Amore V, Santolini I, Celli R, Lionetto L, De Fusco A, Simmaco M, van Rijn CM, Vieira E, Stauffer SR, Conn PJ, Bosco P, Nicoletti F, van Luijtelaar G, Ngomba RT. Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats. Neuropharmacology. 2014 Oct;85:91-103. doi: 10.1016/j.neuropharm.2014.05.005. Epub 2014 May 20. PubMed PMID: 24859611; PubMed Central PMCID: PMC4356528. 10: Ji G, Neugebauer V. CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model. Eur J Neurosci. 2014 Feb;39(3):455-66. doi: 10.1111/ejn.12432. PubMed PMID: 24494685; PubMed Central PMCID: PMC4288820. 11: Notartomaso S, Zappulla C, Biagioni F, Cannella M, Bucci D, Mascio G, Scarselli P, Fazio F, Weisz F, Lionetto L, Simmaco M, Gradini R, Battaglia G, Signore M, Puliti A, Nicoletti F. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol Brain. 2013 Nov 19;6:48. doi: 10.1186/1756-6606-6-48. PubMed PMID: 24252411; PubMed Central PMCID: PMC4225515. 12: D'Amore V, Santolini I, van Rijn CM, Biagioni F, Molinaro G, Prete A, Conn PJ, Lindsley CW, Zhou Y, Vinson PN, Rodriguez AL, Jones CK, Stauffer SR, Nicoletti F, van Luijtelaar G, Ngomba RT. Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats. Neuropharmacology. 2013 Mar;66:330-8. doi: 10.1016/j.neuropharm.2012.05.044. Epub 2012 Jun 15. PubMed PMID: 22705340; PubMed Central PMCID: PMC3787880. 13: Kiritoshi T, Sun H, Ren W, Stauffer SR, Lindsley CW, Conn PJ, Neugebauer V. Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. Neuropharmacology. 2013 Mar;66:170-8. doi: 10.1016/j.neuropharm.2012.03.024. Epub 2012 Apr 6. PubMed PMID: 22521499; PubMed Central PMCID: PMC3568505. 14: Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010 Dec;78(6):1105-23. doi: 10.1124/mol.110.067207. Epub 2010 Oct 5. PubMed PMID: 20923853; PubMed Central PMCID: PMC2993468.